NEW YORK (Reuters Health) – Adding camrelizumab to chemotherapy improves overall survival and progression-free survival when used as first-line therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC), according to results of the ESCORT-1st study conducted in China. ESCC…